Determine the necessary mass, volume, or concentration for preparing a solution.
CT52923 - ≥98% , CAS No.205256-55-9
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
In Vitro
CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC 50 value of 100 to 200 nM. CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC 50 of 64 and 280 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration AssayCell Line: Rat A10 smooth muscle cells Concentration: 0.01-30 μM Incubation Time: 24 h Result: Inhibited PDGF-induced cell migration with an IC 50 of 64 nM.
In Vivo
CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carotid artery balloon angioplasty model . Dosage: 5, 15, 30, and 50 mg/kg Administration: Oral gavage; twice daily Result: Inhibited PDGF-mediated response to vascular injury.
Form:Solid
Specifications
Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomeruloneph
Storage
Protected from light, Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Purity
≥98%
Names and Identifiers
| Molecular Weight | 467.54 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.